Ankylosing Spondylitis

Featured Article
When TNFi Doses are Reduced, Ankylosing Spondylitis Medical Costs Decrease
“The cost of AS-related total medical care significantly increased medical cost savings from 24.85% to 35.52% following TNFi dose reduction,” researchers concluded.
Biologic Strategies for Ankylosing Spondylitis Not Cost-Effective at Common Threshold
No biologic strategies in treatment guidelines for ankylosing spondylitis were cost-effective at a willingness-to-pay threshold of $100,000 per quality-adjusted life-year.
Switching or Discontinuing Ankylosing Spondylitis Biologics Raises Medical Costs
Patients with ankylosing spondylitis who switch or discontinue their biologic within a year of starting it have higher health care utilization and medical costs compared with patients who stay with…

Newsfeed

When TNFi Doses are Reduced, Ankylosing Spondylitis Medical Costs Decrease
Biologic Strategies for Ankylosing Spondylitis Not Cost-Effective at Common Threshold
Switching or Discontinuing Ankylosing Spondylitis Biologics Raises Medical Costs
Understanding the Link Between bDMARD Initiation, Switching With Mood Disorders
Disease Activity in Axial Spondylarthritis Patients Linked With Current State of Health Care Stress
Ankylosing Spondylitis Improvement Sustained After 5 Years of Secukinumab Treatment
Switching SC-TNFi Associated With Higher Nontreatment HCRU Costs
Chronic Opioid Use in Ankylosing Spondylitis Is Concerning
View More
Back to Top